Companies Dominating the Dravet Syndrome Treatment Landscape
- AbbVie Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Cadila Healthcare Ltd.
- Encoded Therapeutics Inc.
- Epygenix Therapeutics Inc.
- H Lundbeck AS
- Jazz Pharmaceuticals Plc
- Johnson and Johnson
- Lupin Ltd.
- PTC Therapeutics Inc.
- Stoke Therapeutics Inc.
- Supernus Pharmaceuticals Inc.
- Sun Pharmaceutical Industries Ltd.
Browse Key Market Insights with Data Illustration:
In the News
- Cadila Healthcare Ltd. an innovative, global pharmaceutical company received approval from the USFDA for a seizure treatment drug, vigabatrin tablets in the strength of 500 mg, which is capable of reducing the frequency of seizures in both adults and kids who haven't been able to manage their seizures with existing treatments by preventing the breakdown of GABA, a naturally occurring tranquilizer, in the brain.
- Encoded Therapeutics Inc. received over USD 130 million to fund the initial human clinical studies of ETX101, which was given classifications as an orphan drug and a rare pediatric condition by the American Food and Drug Administration (FDA). Furthermore, ETX101 was created to raise NaV1.1-alpha levels to prepare it for the clinic and beyond, and to attract some of the most knowledgeable senior leaders in gene therapy.
